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Although the incidence of end stage renal failure in
patients with autoinflammatory diseases has decreased
since the introduction of the interleukin-1 (IL-1)-receptor
antagonist anakinra, it is still relatively common. Cessation
of anti-IL-1 therapy during and after kidney transplanta-
tion will not be possible in most patients because of the
risk of recurrence of inflammation. The effect of continued
anti-IL-1 therapy on transplantation-related complications
is currently unknown.
Recently, we have performed kidney transplantation in
two patients while on anakinra therapy. The first patient is
a 70 year old male, who suffered from febrile episodes
since 2004 and was diagnosed with adult onset Still’s dis-
ease in 2010. He had been using anakinra ever since.
Chronic renal insufficiency due to thrombotic microangio-
pathy had been present since 2005. In September 2014 he
received a kidney transplant of a living related donor,
under standard immunosuppression (tacrolimus, predni-
sone and mycophenolate mofetil (MMF)), while anakinra
was continued. Kidney function improved rapidly and he
could be discharged from the hospital 7 days post trans-
plantation. Until March 2015, he has been readmitted two
times: once for a single day because of drainage of a
wound abscess, and for 5 days 1 year post-transplantation
because of sepsis with unknown cause. He now has ade-
quate and stable transplant function.
The other patient is a 20 year old woman with mutation-
negative Chronic Infantile Neurologic Cutaneous Articular
(CINCA) syndrome. She had been using anakinra since
2004, which was switched to canakinumab in 2012. She
was known with chronic renal insufficiency with protei-
nuria, probably due to recurrent urinary tract infections,
vesico-urethral reflux and chronic use of NSAIDs since
2009. Kidney biopsy was contra-indicated. Because of
rapidly progressive renal function loss, she received a
pre-emptive kidney transplant of a healthy related donor in
September 2014, under standard immunosuppression.
Canakinumab was switched to anakinra just before trans-
plantation, because of shorter half-life, making it easier to
cease in case of complications. Kidney function increased
rapidly and she could be discharged 6 days post-transplan-
tation. She had been readmitted a single time for two days
because of a primo-EBV and influenza infection in
December 2014. She now has normal kidney function.
In these two cases we did not find an increase of trans-
plantation-related complications or post-transplantation
infectious complications, when kidney transplantation
with a standard immunosuppresive regimen was per-
formed during anakinra therapy. It is important to adapt
the dosing of anakinra to the kidney function before and
after transplantation.
Written informated consent for publication of their
clinical details was obtained from the patient/parent/
guardian/relative of the patient.
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